News
The Center for Medicare and Medicaid Services had proposed raising its hospice payment rates, a key revenue stream for Amedisys, by 2.7%. Amedisys’ stock price was $172 at the end of the month.
Net service revenue decreased $4.9 million to $553.0 million compared to $557.9 million in 2022. Net loss attributable to Amedisys, Inc. of $80.3 million, which is inclusive of $125.5 million in ...
Hosted on MSN1mon
Amedisys (AMED) Lags Q4 Earnings and Revenue Estimates - MSNAmedisys (AMED) came out with quarterly earnings of $0.96 per share, missing the Zacks Consensus Estimate of $1.05 per share. This compares to earnings of $0.94 per share a year ago. These figures ...
Amedisys, Inc. reported a rise in net service revenue for Q3 2024, reaching $587.7 million, up from $556.2 million in 2023, despite merger-related expenses impacting net income, which fell to $16. ...
Optum's new buyout offer is competing with another buyout offer from Option Care Health. This latest offer would be a $3.26 billion all-cash deal. Amedisys reported revenue growth of 2% in the ...
Hosted on MSN11mon
AMED Stock Earnings: Amedisys Beats EPS, Beats Revenue for Q2 2024 - MSNAmedisys reported earnings per share of $1.32. This was above the analyst estimate for EPS of $1.18. The company reported revenue of $591.19 million. This was 2.14% better than the analyst ...
Amedisys reported a net revenue of $553 million in the second quarter, which reflects a decrease of 0.9 percent over the same period of 2022.
While the company's revenue growth has been modest at 0.32% over the last twelve months as of Q3 2023, the stability in revenue streams is a positive sign for investors looking for steady performance.
Amedisys President and CEO Chris Gerard has been "terminated without cause," the home care company reported to the Securities and Exchange Commission.
The Center for Medicare and Medicaid Services had proposed raising its hospice payment rates, a key revenue stream for Amedisys, by 2.7%. Amedisys’ stock price was $172 at the end of the month.
BATON ROUGE, La., July 27, 2022 (GLOBE NEWSWIRE) -- Amedisys, Inc. (NASDAQ: AMED) today reported its financial results for the three and six-month periods ended June 30, 2022. Three-Month Periods ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results